查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1867182

卡纳万病治疗市场按治疗方法、给药途径、分销管道、最终用户、治疗线、开发商类型、技术和患者年龄组划分 - 全球预测 2025-2032

Canavan Disease Therapeutics Market by Therapy Type, Route Of Administration, Distribution Channel, End User, Therapy Line, Developer Type, Technology, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，卡纳万病治疗市场将成长至 8.9437 亿美元，复合年增长率为 6.10%。

关键市场统计数据
基准年 2024 5.5666亿美元
预计年份：2025年 5.9107亿美元
预测年份 2032 8.9437亿美元
复合年增长率 (%) 6.10%

策略背景及重点：临床与科学挑战如何影响卡纳万病下一代疗法的研发

卡纳万氏症是一种以天冬胺酸代谢酶缺乏所引起的进行性中枢神经系统海绵状进行性为特征的疾病，至今仍是临床上最具挑战性的脑白质营养不良症之一。儘管数十年来已对其进行了分子特征分析，但由于药物难以穿过血脑障壁、自然病史数据有限以及缺乏特征明确的患者队列，治疗方法研发一直受到限制。目前的研发现状反映了一个学习曲线，临床前模型的预测能力比以往任何时候都更强，近年来载体技术、给药方案和生物标记开发方面也取得了显着进展。

载体技术、精准编辑平台以及不断发展的监管和生产模式的进步将如何重塑卡纳万病治疗研发？

随着基因递送、精准编辑和辅助药理学等领域的创新融合，卡纳万病治疗格局正在经历一场变革。载体技术能够更好地靶向中枢神经系统并降低定向，从而实现更可靠的全身和脑实质内给药策略。同时，基因组编辑平台的进步使得开发持久有效的治疗方法成为可能，而小分子调节剂作为免疫抗原性补充策略，在解决代谢异常和缓解症状方面仍然发挥着重要作用。

评估2025年美国关税调整对先进治疗药物供应链动态、筹资策略与生产韧性的影响

2025年美国关税调整对卡纳万病治疗生态系统产生了多方面的影响，改变了关键材料的采购成本结构和物流模式。由于进口关税的提高，专用设备、一次性生物反应器零件和先进试剂的供应商面临到岸成本增加和采购前置作业时间延长的双重压力。由于基因治疗项目依赖高度特定的原材料和跨境供应链，这些关税引发的摩擦导致生产宣传活动的缓衝时间缩短，并需要寻找替代的筹资策略。

综合細項分析，阐述治疗方法类型、给药方式、通路、终端用户环境、开发商类型、技术和患者年龄如何影响策略决策。

了解细分市场的细微差别对于解读卡纳万病治疗方案的治疗机会和营运重点至关重要。依治疗方式分类的治疗方法包括酵素替代疗法、基因疗法和小分子疗法。基因疗法的递送方式根据腺相关病毒（AAV）和慢病毒载体平台而有所不同，而小分子疗法可能专注于锂或N-乙酰半胱胺酸等药物。给药途径是另一个重要方面，包括肌肉注射、静脉注射和口服，每种途径对药物动力学、患者依从性和临床监测的影响各不相同。通路影响药物的可及性和依从性，涵盖医院药房、线上药房和零售药房，所有这些都与报销机制和患者支援服务相关。

区域监管差异、生产能力分配和临床网路成熟度如何影响全球市场的适应性开发和准入策略

区域趋势将对卡纳万病药物研发策略、监管互动和病患用药产生决定性影响。在美洲，临床专业知识和先进製造能力的集中中心构建了一个强大的生态系统，为早期临床试验和商业化计划提供支持，监管路径侧重于基于已建立的罕见疾病机制的快速核准流程。在欧洲、中东和非洲，法规环境不均衡，先进的临床网络和不同的报销制度要求申办方根据不同地区调整证物材料和用药策略。在亚太地区，新兴的临床试验能力、不断发展的生物技术生态系统以及扩大本地生产的努力，为可扩展且经济高效的生产创造了极具吸引力的选择，但监管协调仍然是一项持续的挑战。

具有竞争力的企业级洞察，揭示科学专长、伙伴关係策略和製造联盟如何决定专案进度和生态系统合作。

在卡纳万病领域，主要企业在科学研究重点、生产策略和伙伴关係模式方面展现出差异化的发展路径。一些开发人员强调载体工程和基因组编辑平台的深度，大力投资于临床前检验和载体优化，以确保中枢神经系统持续表达和良好的安全性。另一些公司则优先考虑转化应用的灵活性，将已用于治疗卡纳万病的小分子药物与支持性治疗相结合，以减轻症状负担并扩大治疗窗口，同时推进基因治疗计画的成熟。整体而言，专业生技研发公司与大型製药公司之间的合作十分普遍，这种合作模式将深厚的科研专长与商业基础设施和医保支付方沟通能力结合。

产业领导者提升罕见疾病计画供应链韧性、监管合规性、病人参与和生产规模化的实用方法

产业领导者应采取一系列切实可行的策略，推动复杂的卡纳万病治疗药物的研发和商业化。首先，必须优先考虑供应链的韧性。透过对多家供应商进行资格认证、投资建设地域分散的生产能力以及製定稳健的关键原材料库存计划，可以降低专案风险。其次，儘早与监管机构就可接受的替代终点和适应性研究设计进行协调，可以降低临床实验风险并提高研发进度的可预测性。第三，将病患权益组织纳入通讯协定共同设计和自然史研究，可以提高试验的相关性，加快病患招募速度，并加强真实世界资料的收集。

策略结论和建议透过透明的混合方法调查方法检验，该方法结合了文献综合、专家访谈和严格的检验。

本研究采用混合方法，结合了全面的二手文献综述、一手质性访谈和严格的交叉检验。二手文献包括同行评审的科学文献、监管指导文件、会议报告和技术白皮书，用于建立科学和监管背景。一手研究包括对脑白质营养不良症临床医生、病毒载体生产专家、监管事务负责人、医保专家和患者权益倡导者进行结构化访谈，以获取实践见解、优先排序标准和实际限制。

最后总结发言指出，需要具备营运韧性、策略协同和实用化协调能力，才能将科学进步转化为对病人的影响。

卡纳万病有效治疗方法的研发，取决于技术创新、以患者为中心的试验设计以及切实可行的操作执行三者之间的交汇点。载体设计、基因组编辑和辅助药理学的科学进步已催生出多种可靠的治疗途径，但成功的实用化需要对生产规模、监管策略和患者参与度给予足够的重视。诸如关税引发的采购挑战等短期干扰，凸显了建构具有韧性的供应链和区域生产策略的必要性。同时，监管的灵活性和试验设计的进步，为在不降低证据品质的前提下加速研发创造了机会。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 针对ASPA基因修復的基因疗法临床试验取得进展
  • 专注于中枢神经系统髓鞘保护的创新小分子化合物
  • FDA快速通道计画下AAV介导的罕见神经系统疾病疗法的监管审查进展
  • 与一家生物技术Start-Ups和学术机构合作，对卡纳万病进行生物标记检验
  • 患者权益倡导组织致力于资金筹措并提高公众对卡纳万病临床研究的认识。
  • 利用机器学习演算法优化卡纳万病酶替代疗法的剂量方案
  • 开发用于卡纳万病中枢神经系统标靶化基因转移的脂质奈米颗粒递送平台

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 卡纳万病治疗市场（依治疗方法）

  • 酵素替代疗法
  • 基因治疗
    • AAV载体
    • 慢病毒载体
  • 小分子疗法
    • 锂
    • N-乙酰半胱胺酸

9. 卡纳万氏症治疗药物市场（依给药途径划分）

  • 肌肉内注射
  • 静脉注射
  • 口服

第十章 卡纳万病治疗市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 卡纳万病治疗市场（按最终用户划分）

  • 诊所
  • 居家医疗环境
  • 医院

12. 卡纳万病治疗市场（依治疗系列划分）

  • 一线治疗
  • 二级治疗

第十三章 卡纳万病治疗药物市场（按开发商类型划分）

  • 生技公司
  • 製药公司

14. 卡纳万病治疗市场（依技术划分）

  • CRISPR-Cas9
  • 塔伦
  • ZFN

第十五章 卡纳万病治疗市场（依患者年龄层划分）

  • 成年患者
  • 儿科患者

第十六章 卡纳万病治疗市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章 卡纳万病治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章 各国卡纳万病治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章 竞争情势

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Ionis Pharmaceuticals, Inc.
    • Aspa Therapeutics
    • Contera Pharma
    • RegenxBio
    • Novartis AG
    • Biogen Inc.
    • Rocket Pharmaceuticals
Product Code: MRR-99555D550525

The Canavan Disease Therapeutics Market is projected to grow by USD 894.37 million at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 556.66 million
Estimated Year [2025] USD 591.07 million
Forecast Year [2032] USD 894.37 million
CAGR (%) 6.10%

A focused orientation to the clinical and scientific imperatives shaping next-generation therapeutic development for Canavan disease with strategic context

Canavan disease remains one of the most clinically challenging leukodystrophies, characterized by progressive spongiform degeneration of the central nervous system driven by aspartoacylase deficiency. Despite decades of molecular characterization, therapeutic development has been constrained by blood-brain barrier delivery challenges, limited natural history datasets, and the rarity of well-characterized patient cohorts. The current development landscape reflects a learning curve: preclinical models are more predictive than before, and vectorology, dosing paradigms, and biomarker development have advanced materially over the last several years.

As clinical teams translate mechanistic insights into human studies, industry stakeholders must reconcile scientific potential with operational realities. Manufacturing capacity for viral vectors, standardization of outcome measures, and alignment with rare-disease regulatory pathways are immediate priorities. In parallel, patient advocacy groups and clinician networks are increasingly shaping trial design and recruitment strategies, enabling more patient-centric approaches. Taken together, these elements frame a high-stakes but increasingly navigable pathway from bench to bedside for Canavan disease therapeutics.

How advances in vector technology, precision editing platforms, and evolving regulatory and manufacturing paradigms are reshaping Canavan disease therapeutic development

The therapeutic landscape for Canavan disease is undergoing transformative shifts as innovations in gene delivery, precision editing, and supportive pharmacology converge. Vector technologies have evolved to offer improved central nervous system tropism and reduced immunogenicity, enabling more credible systemic and intraparenchymal delivery strategies. Concurrently, advances in genome editing platforms permit exploration of permanent corrective approaches, while small molecule modulation remains relevant as a complementary strategy to address metabolic dysregulation and symptomatic needs.

Regulatory and payer frameworks are also adapting to rare disease realities. Accelerated approval pathways, adaptive trial design options, and expanded access mechanisms are influencing developmental timelines and commercial planning. Meanwhile, manufacturing innovations-such as scalable vector production and modular cell-processing workflows-are de-risking supply constraints that historically impeded progress. These converging shifts are changing how sponsors prioritize programs, allocate capital, and engage with clinical networks, ultimately creating a more dynamic environment for translating promising science into viable therapies.

An assessment of how the 2025 United States tariff adjustments altered supply chain dynamics, procurement strategies, and manufacturing resilience for advanced therapeutics

United States tariff changes implemented in 2025 have exerted a multifaceted influence on the Canavan disease therapeutic ecosystem by altering the cost structure and logistics of sourcing critical inputs. Suppliers of specialized equipment, single-use bioreactor components, and advanced reagents faced elevated import duties that increased landed costs and extended procurement lead times. Because gene therapy programs rely on highly specific raw materials and cross-border supply chains, these tariff-driven frictions translated into tighter scheduling buffers for manufacturing campaigns and a need for alternative sourcing strategies.

In response, sponsors and contract development and manufacturing organizations have accelerated nearshoring initiatives and diversified supplier bases to mitigate supply chain concentration risk. This operational pivot has implications for program budgets and timeline management, as qualification of new suppliers and revalidation of processes require time and investment. At the same time, clinical operations teams have recalibrated inventory strategies for critical supplies to prevent trial disruptions. While tariffs introduced short-term headwinds, they also prompted a strategic reassessment of supply resilience and have catalyzed investments in domestic capacity expansion and procurement agility that could yield longer-term benefits for rare disease program continuity.

Integrated segmentation analysis explaining how therapy modality, delivery approach, distribution, end user settings, developer type, technology and patient age inform strategic decisions

A nuanced understanding of segmentation is essential to interpret therapeutic opportunity and operational priorities across Canavan disease programs. When therapies are categorized by treatment modality, the field includes enzyme replacement therapy, gene therapy, and small molecule therapy; within gene therapy, delivery approaches are differentiated by AAV vector and lentiviral vector platforms, while small molecule programs may focus on lithium or N-acetylcysteine as pharmacologic approaches. Route of administration is another critical axis, encompassing intramuscular, intravenous, and oral modalities, each with distinct implications for pharmacokinetics, patient adherence, and clinical monitoring. Distribution channels shape access and adherence pathways, spanning hospital pharmacies, online pharmacies, and retail pharmacies, all of which interact with reimbursement mechanisms and patient support services.

End user dynamics-clinics, homecare settings, and hospitals-inform both delivery feasibility and real-world evidence generation, while therapy line classification into first-line and second-line treatments determines clinical positioning and payer negotiation strategies. Developer type separates approaches by biotech companies and pharmaceutical companies, with differences in risk tolerance, vertical capabilities, and commercialization reach. Technology platforms such as CRISPR-Cas9, TALEN, and ZFN provide mechanistic differentiation that affects regulatory engagement and intellectual property strategies. Finally, patient age group stratification into adult and pediatric populations drives distinct clinical trial designs, outcome measures, and safety monitoring frameworks. Together, these segmentation dimensions create an interlocking framework that guides program design, clinical development priorities, and commercialization tactics.

How regional regulatory variability, manufacturing capacity allocation, and clinical network maturity influence adaptive development and access strategies across global markets

Regional dynamics have a determinative effect on development strategies, regulatory interactions, and patient access for Canavan disease therapeutics. In the Americas, concentrated centers of clinical expertise and advanced manufacturing capacity underpin a strong ecosystem for early-phase testing and commercialization planning, and regulatory pathways emphasize established rare disease mechanisms for expedited engagement. Europe, Middle East & Africa present heterogenous regulatory environments with pockets of advanced clinical networks and reimbursement variability, prompting sponsors to tailor evidence packages and access strategies region by region. In the Asia-Pacific region, emerging clinical trial capacity, growing biotech ecosystems, and efforts to expand local manufacturing create compelling options for scale and cost-efficient production, although regulatory harmonization remains a work in progress.

These regional distinctions affect everything from trial site selection and patient recruitment to supply chain routing and pricing strategy. As a result, cross-regional planning is now a core competency for sponsors, requiring harmonized data standards, pragmatic regulatory submission planning, and culturally competent patient engagement approaches. Strategic partnerships with regional clinical networks and contract manufacturers can accelerate program timelines while managing regulatory and commercial complexity across distinct geographies.

Competitive company-level insights revealing how scientific specialization, partnership strategies, and manufacturing partnerships define program advancement and ecosystem collaboration

Leading companies operating in the Canavan disease space demonstrate differentiated approaches across scientific focus, manufacturing strategy, and partnership models. Some developers emphasize platform depth in vector engineering and genome editing, investing heavily in preclinical validation and vector optimization to secure durable CNS expression and favorable safety profiles. Others prioritize translational agility by combining repurposed small molecules with supportive therapies to address symptom burden and extend therapeutic windows while gene-based programs mature. Across the board, partnerships between specialized biotech developers and larger pharmaceutical organizations are common, aligning deep scientific expertise with commercial infrastructure and payer engagement capabilities.

Contract development and manufacturing organizations have become indispensable partners, providing scalability and technical know-how for vector production and quality systems. Patient advocacy groups and clinical centers of excellence play a parallel role by contributing to natural history studies, facilitating trial recruitment, and shaping patient-reported outcome measures. Collectively, these stakeholders form an ecosystem in which collaboration, platform specialization, and operational excellence determine program momentum and long-term viability.

Actionable approaches for industry leaders to strengthen supply resilience, regulatory alignment, patient engagement and manufacturing scalability for rare disease programs

Industry leaders should pursue a set of actionable strategies to navigate the complex therapeutic development and commercialization pathway for Canavan disease. First, prioritizing supply chain resilience is essential: qualifying multiple suppliers, investing in regionally diversified manufacturing capacity, and developing robust inventory planning for critical raw materials will reduce program vulnerability. Second, aligning early with regulators on acceptable surrogate endpoints and adaptive trial designs can de-risk pivotal pathways and improve predictability for development timelines. Third, integrating patient advocacy groups into protocol co-design and natural history studies will increase trial relevance, accelerate recruitment, and strengthen real-world evidence capture.

In addition, companies should adopt modular manufacturing and platform-based approaches to maximize vector productivity and reduce per-batch variability, while pursuing cross-program learnings to shorten development cycles. Commercially, tailoring market access strategies to regional payer expectations and distribution infrastructures will improve adoption potential. Finally, investing in biomarker development and long-term follow-up frameworks will create clearer durability and safety narratives, which are critical for payer acceptance and for establishing sustainable reimbursement models. Implementing these actions in a coordinated manner will materially improve the probability of clinical and commercial success.

A transparent mixed-methods research approach combining literature synthesis, expert interviews, and rigorous triangulation to validate strategic conclusions and recommendations

This research employed a mixed-methods approach combining comprehensive secondary literature synthesis with primary qualitative interviews and rigorous cross-validation. Secondary inputs included peer-reviewed scientific literature, regulatory guidance documents, conference proceedings, and technical whitepapers to establish the scientific and regulatory context. Primary research consisted of structured interviews with clinicians specializing in leukodystrophies, manufacturing experts in viral vector production, regulatory affairs professionals, reimbursement specialists, and patient advocacy leaders to capture operational insights, prioritization criteria, and real-world constraints.

Findings were triangulated across data sources to minimize bias, and methodological rigor was maintained through standardized interview guides, anonymized respondent coding, and thematic analysis to distill convergent insights. Quality assurance included expert review by senior analysts with domain experience and iterative validation of conclusions against emerging public disclosures. Where appropriate, sensitivity checks and scenario mapping were used to test the robustness of strategic recommendations. The methodology emphasizes transparency, reproducibility, and a clear linkage between evidence and strategic conclusions.

Concluding perspectives on the imperative of operational resilience, strategic collaboration, and translational alignment to convert scientific advances into patient impact

Developing effective therapies for Canavan disease sits at the intersection of technical innovation, patient-centered trial design, and pragmatic operational execution. Scientific progress in vector design, genome editing, and supportive pharmacology has created multiple credible therapeutic avenues, but successful translation requires deliberate attention to manufacturing scale, regulatory strategy, and patient engagement. Short-term disruptions such as tariff-induced procurement challenges have underscored the need for resilient supply chains and regional manufacturing strategies, while advances in regulatory flexibility and trial design create opportunities to accelerate development without compromising evidence quality.

In summary, the ecosystem is poised for meaningful progress provided stakeholders align on robust operational frameworks, invest in manufacturing and biomarker infrastructure, and deepen collaboration with clinical and patient communities. These elements together can transform promising scientific advances into durable clinical options for patients living with Canavan disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in gene therapy clinical trials targeting ASPA gene restoration
  • 5.2. Innovative small molecule compounds focusing on myelin preservation in the central nervous system
  • 5.3. Regulatory review progress of AAV-mediated therapies for rare neurological disorders in FDA fast track programs
  • 5.4. Collaborations between biotech startups and academic institutions for biomarker validation in Canavan disease
  • 5.5. Patient advocacy initiatives driving increased funding and awareness for Canavan disease clinical research
  • 5.6. Application of machine learning algorithms to optimize dosing regimens for enzyme replacement therapy in Canavan disease
  • 5.7. Development of lipid nanoparticle delivery platforms for targeted central nervous system gene transfer in Canavan disease

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Canavan Disease Therapeutics Market, by Therapy Type

  • 8.1. Enzyme Replacement Therapy
  • 8.2. Gene Therapy
    • 8.2.1. Aav Vector
    • 8.2.2. Lentiviral Vector
  • 8.3. Small Molecule Therapy
    • 8.3.1. Lithium
    • 8.3.2. N-Acetylcysteine

9. Canavan Disease Therapeutics Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Oral

10. Canavan Disease Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Canavan Disease Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Homecare Settings
  • 11.3. Hospitals

12. Canavan Disease Therapeutics Market, by Therapy Line

  • 12.1. First-Line
  • 12.2. Second-Line

13. Canavan Disease Therapeutics Market, by Developer Type

  • 13.1. Biotech Companies
  • 13.2. Pharma Companies

14. Canavan Disease Therapeutics Market, by Technology

  • 14.1. Crispr-Cas9
  • 14.2. Talen
  • 14.3. Zfn

15. Canavan Disease Therapeutics Market, by Patient Age Group

  • 15.1. Adult Patients
  • 15.2. Pediatric Patients

16. Canavan Disease Therapeutics Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Canavan Disease Therapeutics Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Canavan Disease Therapeutics Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Ionis Pharmaceuticals, Inc.
    • 19.3.2. Aspa Therapeutics
    • 19.3.3. Contera Pharma
    • 19.3.4. RegenxBio
    • 19.3.5. Novartis AG
    • 19.3.6. Biogen Inc.
    • 19.3.7. Rocket Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. CANAVAN DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. CANAVAN DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANAVAN DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST CANAVAN DISEAS